moneyheap
CDNA · Analysis updated Oct 30, 2026, 10:45 AM ET
Why is CareDx, Inc. (CDNA) stock moving?
CareDx's sales grew 39% and profit nearly tripled forecasts, so it raised its full-year goals. The business is clearly working. The catch is that the stock is up about 5x in a year, so a lot of good news is already in the price.
News behind the analysis
- CareDx Stock Soars 24% as Testing Revenue Jumps 65% and Transplant Test Maker Lifts 2026 Sales OutlookShares +24% to ~$88.50, above prior 52-week high of $73.43; ~$250M cash, no debt; transplant volume +21%.
- CareDx Q3 Revenue Jumps 39%; Raises FY26 Revenue, EBITDA Guidance; Stock UpFY26 revenue guide $520-530M (from $490-500M); adjusted EBITDA guide $90-100M (from $66-78M).
- CareDx Q3 2026 slides: 39% revenue growth, guidance raised $30MFlags $14.7M of out-of-period revenue; NavDx integration a key execution priority.
- BTIG raises CareDx stock price target to $92 on strong executionBTIG target to $92 (Buy); Canaccord to $99 (Buy); EPS $0.70 vs $0.26 expected.
- CareDx (CDNA) Shares Surge 15% on Strong Q3 Earnings BeatValuation caution: trades far above GF Value estimate; insiders sold ~$13.3M in 12 months.
In the Daily Standout
- October 30, 2026: on the shortlist +23.73%